Cargando…

Licensed liposomal vaccines and adjuvants in the antigen delivery system

Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasnopolsky, Yuriy, Pylypenko, Daria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837556/
https://www.ncbi.nlm.nih.gov/pubmed/36685697
http://dx.doi.org/10.5114/bta.2022.120709
_version_ 1784869106745344000
author Krasnopolsky, Yuriy
Pylypenko, Daria
author_facet Krasnopolsky, Yuriy
Pylypenko, Daria
author_sort Krasnopolsky, Yuriy
collection PubMed
description Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are available on the pharmaceutical market. This review focuses on the adjuvant properties of LSs in the production of vaccines (VACs). LS-VACs have the following advantages: antigens with low immunogenicity can become highly immunogenic; LSs can include both hydrophilic and hydrophobic antigens; LSs allow to achieve a prolonged specific action of antibodies; and LSs reduce the toxicity and pyrogenicity of encapsulated antigens and adjuvants. The immune response is influenced by the composition of the liposomal membrane, physicochemical characteristics of lipids, antigen localization in LSs, interaction of LSs with complement, and a number of proteins, which leads to opsonization. The major requirements for adjuvants are their ability to enhance the immune response, biodegradability, and elimination from the organism, and LSs fully meet these requirements. The effectiveness and safety of LSs as carriers in the antigen delivery system have been proven by the long-term clinical use of licensed vaccines against hepatitis A, influenza, herpes zoster, malaria, and COVID-19.
format Online
Article
Text
id pubmed-9837556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-98375562023-01-20 Licensed liposomal vaccines and adjuvants in the antigen delivery system Krasnopolsky, Yuriy Pylypenko, Daria BioTechnologia (Pozn) Review Papers Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are available on the pharmaceutical market. This review focuses on the adjuvant properties of LSs in the production of vaccines (VACs). LS-VACs have the following advantages: antigens with low immunogenicity can become highly immunogenic; LSs can include both hydrophilic and hydrophobic antigens; LSs allow to achieve a prolonged specific action of antibodies; and LSs reduce the toxicity and pyrogenicity of encapsulated antigens and adjuvants. The immune response is influenced by the composition of the liposomal membrane, physicochemical characteristics of lipids, antigen localization in LSs, interaction of LSs with complement, and a number of proteins, which leads to opsonization. The major requirements for adjuvants are their ability to enhance the immune response, biodegradability, and elimination from the organism, and LSs fully meet these requirements. The effectiveness and safety of LSs as carriers in the antigen delivery system have been proven by the long-term clinical use of licensed vaccines against hepatitis A, influenza, herpes zoster, malaria, and COVID-19. Termedia Publishing House 2022-12-24 /pmc/articles/PMC9837556/ /pubmed/36685697 http://dx.doi.org/10.5114/bta.2022.120709 Text en © 2022 Institute of Bioorganic Chemistry, Polish Academy of Sciences https://creativecommons.org/licenses/by-nc-nd/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), allowing third parties to download and share its works but not commercially purposes or to create derivative works.
spellingShingle Review Papers
Krasnopolsky, Yuriy
Pylypenko, Daria
Licensed liposomal vaccines and adjuvants in the antigen delivery system
title Licensed liposomal vaccines and adjuvants in the antigen delivery system
title_full Licensed liposomal vaccines and adjuvants in the antigen delivery system
title_fullStr Licensed liposomal vaccines and adjuvants in the antigen delivery system
title_full_unstemmed Licensed liposomal vaccines and adjuvants in the antigen delivery system
title_short Licensed liposomal vaccines and adjuvants in the antigen delivery system
title_sort licensed liposomal vaccines and adjuvants in the antigen delivery system
topic Review Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837556/
https://www.ncbi.nlm.nih.gov/pubmed/36685697
http://dx.doi.org/10.5114/bta.2022.120709
work_keys_str_mv AT krasnopolskyyuriy licensedliposomalvaccinesandadjuvantsintheantigendeliverysystem
AT pylypenkodaria licensedliposomalvaccinesandadjuvantsintheantigendeliverysystem